Sponsored Links

In Letter to Congress, NORD Urges Action on Healthcare Reform

* Reuters is not responsible for the content in this press release.

Fri Jul 31, 2009 3:49pm EDT

DANBURY, Conn., July 31 /PRNewswire-USNewswire/ -- The following letter
regarding health care reform was sent to all members of Congress today by the
National Organization for Rare Disorders (NORD):

July 31, 2009


Dear Member of Congress:

On behalf of the 30 million Americans who are affected by one of the nearly
7,000 rare disorders, we urge you to pass comprehensive health reform
legislation designed to assure that every American, regardless of health
status, has access to affordable, meaningful health insurance coverage. 
Failure to pass such long-overdue legislation this year would be devastating
and an unacceptable option for people with rare diseases and their families,
as well as the millions of other Americans who similarly are burdened by
chronic illness. 

Today, far too many people under the age of 65 with serious medical conditions
have inadequate or no access to health insurance.  In most areas of the
country, in the absence of employer-based coverage, medical underwriting
practices by insurers can, and too often do, result in pre-existing condition
limits on coverage, higher health insurance premiums and, for many, outright
denials of coverage.  People with rare diseases customarily incur substantial
medical expenses, first in efforts to obtain an accurate diagnosis, and
thereafter from hospitalizations, physicians' office visits, and -- for those
fortunate enough to have a therapeutic drug, biological, device or medical
food -- from costs of these treatments, some of which amount to tens of
thousands of dollars per year.

As such, for people with rare diseases -- and indeed for all Americans --
three basic principles should be part of any acceptable reform.  First, health
reform must prohibit insurance companies from denying or limiting coverage, or
charging patients more for premiums based on health status.  Second, patients
must be protected against catastrophic out-of-pocket costs and annual or
lifetime insurance caps.  Third, health reform must include tax credits and
other direct financing support sufficient to assure that lower and middle
income patients can afford coverage.  

We recognize and accept that with these critically important health care
benefits comes an individual responsibility to purchase health insurance. 
Moreover, NORD will be a constructive force in supporting measures that
provide for necessary savings and revenues to ensure that these benefits are
paid for and managed in a fiscally prudent fashion.  

We are pleased that many Congressional leaders are pursuing policies that
achieve NORD's principles.  While comprehensive federal health reform cannot
be all things to all people, it must not be an empty promise to Americans,
including those who currently suffer from, and those who will develop, rare
diseases.

Finally, we understand and accept that compromises will be made as health
reform legislation makes its way through the legislative process.  While the
basic patient protections outlined above are fundamental to any reform, we
recognize that there will be design approaches that would not be our first
choice.  However, we pledge that we will not allow the perfect to be the enemy
of the good.   To be clear, though, we also strongly believe that failure to
act is an explicit policy choice to preserve the unacceptable status quo. 
Such a choice has dire access and cost consequences that are intolerable for
individuals, families, and the country.   

We thank you for your commitment to meaningful health reform.  We are eager to
work with you to assure passage of legislation that makes health insurance
affordable and accessible for every American, regardless of health status.  

Sincerely,

Peter L. Saltonstall
President and CEO
National Organization for Rare Disorders (NORD)


SOURCE  National Organization for Rare Disorders (NORD)

Mary Dunkle of the National Organization for Rare Disorders, +1-203-744-0100
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.